TXG Logo

10x Genomics, Inc. (TXG) 

NASDAQ
Market Cap
$2.02B
Sector
Healthcare
Industry
Medical—Healthcare Information Services
Rank in Sector
396 of 776
Rank in Industry
16 of 32

Largest Insider Buys in Sector

TXG Stock Price History Chart

TXG Stock Performance

About 10x Genomics, Inc.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for …

Insider Activity of 10x Genomics, Inc.

Over the last 12 months, insiders at 10x Genomics, Inc. have bought $0 and sold $3.13M worth of 10x Genomics, Inc. stock.

On average, over the past 5 years, insiders at 10x Genomics, Inc. have bought $12,793 and sold $283.56M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 158 shares for transaction amount of $6,397 was made by McAnear Justin J. (Chief Financial Officer) on 2022‑05‑13.

List of Insider Buy and Sell Transactions, 10x Genomics, Inc.

2024-08-22SaleChief Executive Officer
6,749
0.0057%
$22.53$152,053-3.53%
2024-08-22SaleSee Remarks
4,351
0.0037%
$22.53$98,027-3.53%
2024-08-22SaleFormer Chief Financial Officer
2,961
0.0025%
$22.53$66,710-3.53%
2024-05-22SaleChief Executive Officer
4,877
0.0041%
$24.30$118,529-15.02%
2024-05-22SaleSee Remarks
4,087
0.0034%
$24.30$99,329-15.02%
2024-05-22SaleChief Financial Officer
2,936
0.0025%
$24.30$71,355-15.02%
2024-03-04SaleChief Executive Officer
4,660
0.0038%
$44.00$205,021-49.59%
2024-02-22SaleChief Executive Officer
2,821
0.0028%
$46.34$130,737-50.21%
2024-02-22SaleSee Remarks
2,613
0.0026%
$46.34$121,098-50.21%
2024-02-22SaleChief Financial Officer
1,865
0.0018%
$46.34$86,432-50.21%
2024-02-15SaleChief Executive Officer
5,000
0.0043%
$48.87$244,332-52.56%
2024-02-09SaleChief Executive Officer
1,000
0.001%
$49.53$49,530-53.74%
2024-01-16SaleChief Executive Officer
4,000
0.0034%
$45.24$180,956-45.16%
2023-12-14SaleChief Executive Officer
2,000
0.0017%
$55.03$110,065-51.39%
2023-11-24SaleChief Executive Officer
3,723
0.0032%
$43.72$162,751-36.38%
2023-11-22SaleChief Executive Officer
3,757
0.0032%
$43.34$162,816-36.30%
2023-11-22SaleSee Remarks
3,449
0.0029%
$43.34$149,468-36.30%
2023-11-22SaleChief Financial Officer
1,679
0.0014%
$43.34$72,762-36.30%
2023-11-22SaleChief Commercial Officer
3,464
0.0029%
$43.34$150,118-36.30%
2023-11-20SaleChief Commercial Officer
14,718
0.0121%
$42.09$619,494-36.20%

Insider Historical Profitability

16.57%
McAnear Justin J.Former Chief Financial Officer
143242
0.1183%
$16.68138<0.0001%
Foresite Capital Management I, LLC10 percent owner
2350000
1.9413%
$16.6812+46.56%
ROBERTS BRYAN Edirector
1287825
1.0638%
$16.6811+41.14%
CRUTCHFIELD BRADFORDChief Commercial Officer
97237
0.0803%
$16.68131<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$485.23M10.812.93M+1.12%+$5.39M0.03
The Vanguard Group$341.58M7.69.1M+1%+$3.39M0.01
Baillie Gifford Co$278.65M6.27.42M-6.25%-$18.59M0.22
ARK Investment Management LLC$235.83M5.256.28M+55.49%+$84.16M0.82
BlackRock$225.47M5.026.01M+5.3%+$11.34M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.